Neurocrine Biosciences Inc (NBIX) stock news · P/E 20, rev $2.86B
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
This NBIX news page leads with what Neurocrine Biosciences Inc filed — not a scraped headline mill.
No cached 8-K sentence for NBIX yet. We will not pad this page with generic market recap.
Latest reported NBIX revenue for 2025-12-31 was $2.86B. Net income was $478.6M. Revenue was up 21.4% from 2024-12-31 to 2025-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 20.0.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the NBIX stock page; for the tape open the quote page.
NBIX stock news FAQ
What are NBIX's latest revenue and net income?
Latest cached Neurocrine Biosciences Inc (NBIX) revenue for Dec 31, 2025 was $2.86B. Net income was $478.6M. Statements: https://lician.com/financials/nbix
How did NBIX revenue change from the prior cached period?
Cached Neurocrine Biosciences Inc (NBIX) revenue was up 21.4% from $2.36B (Dec 31, 2024) to $2.86B (Dec 31, 2025). Statements: https://lician.com/financials/nbix
What is NBIX's P/E ratio?
Neurocrine Biosciences Inc (NBIX) trailing P/E is 20.0 on the latest cached fundamentals snapshot.
What is NBIX's market cap?
Neurocrine Biosciences Inc (NBIX) market cap is $13.21B on the latest cached fundamentals snapshot.
What kind of company is NBIX?
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Where is NBIX stock news listed?
Cached stock news for Neurocrine Biosciences Inc (NBIX) is listed at https://lician.com/news/nbix. Filings: https://lician.com/sec/nbix
Not investment advice.